A statement of work has been signed by HTG Molecular Diagnostics and a Qiagen subsidiary to perform initial-phase development work on a sequencing-based companion diagnostic assay. Net profits from the initial phase will be shared by both companies.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.